Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONDRIAN: ctDNA Monitoring in Metastatic Breast Cancer
NCT04720729Phase 2Terminated
- Sponsor
- Institut Curie
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Institut Curie. Primary endpoints: L3C1 : ctDNA quantification, L3C1 : chemotherapy efficacy and 1 more. Started Apr 2021; status: terminated.
Beyond the preview
Go deeper on NCT04720729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720729.